Christopher J Schmidt
Overview
Explore the profile of Christopher J Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wakabayashi Y, Stenkrona P, Arakawa R, Yan X, Van Buskirk M, Jenkins M, et al.
J Nucl Med
. 2022 Jun;
63(12):1919-1924.
PMID: 35772961
Phosphodiesterase-4 (PDE4), which metabolizes the second messenger cyclic adenosine monophosphate (cAMP), has 4 isozymes: PDE4A, PDE4B, PDE4C, and PDE4D. PDE4B and PDE4D have the highest expression in the brain and...
2.
Menniti F, Chappie T, Schmidt C
Front Neurosci
. 2021 Feb;
14:600178.
PMID: 33551724
PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. These neurons dynamically integrate...
3.
Walling D, Banerjee A, Dawra V, Boyer S, Schmidt C, DeMartinis N
J Clin Psychopharmacol
. 2019 Nov;
39(6):575-582.
PMID: 31688451
Background: Current treatments for psychotic symptoms associated with schizophrenia often provide inadequate efficacy with unacceptable adverse effects. Improved therapeutics have long been a goal of research. Preclinical testing suggests that...
4.
Harms J, Menniti F, Schmidt C
Front Neurosci
. 2019 Sep;
13:837.
PMID: 31507355
PDE9A is a cGMP-specific phosphodiesterase expressed in neurons throughout the brain that has attracted attention as a therapeutic target to treat cognitive disorders. Indeed, PDE9A inhibitors are under evaluation in...
5.
DeMartinis 3rd N, Lopez R, Pickering E, Schmidt C, Gertsik L, Walling D, et al.
J Clin Psychopharmacol
. 2019 Jun;
39(4):318-328.
PMID: 31205187
Background: Effective treatments for managing suboptimal clinical responses to current therapy for schizophrenia remain a critical unmet need. Phosphodiesterase 10A (PDE10A) inhibition represents a mechanistically novel approach to the treatment...
6.
Svedberg M, Varnas K, Varrone A, Mitsios N, Mulder J, Gulyas B, et al.
Brain Res
. 2019 Jan;
1711:140-145.
PMID: 30664847
Highly specific and sensitive biomarkers for pathologies related to dysfunctions in the basal ganglia circuit are of great value to assess therapeutic efficacy not only clinically to establish an early...
7.
Helal C, Arnold E, Boyden T, Chang C, Chappie T, Fennell K, et al.
J Med Chem
. 2018 Apr;
61(8):3753.
PMID: 29624389
No abstract available.
8.
Helal C, Arnold E, Boyden T, Chang C, Chappie T, Fisher E, et al.
J Med Chem
. 2018 Jan;
61(3):1001-1018.
PMID: 29293004
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The...
9.
Helal C, Arnold E, Boyden T, Chang C, Chappie T, Fennell K, et al.
J Med Chem
. 2017 Jun;
60(13):5673-5698.
PMID: 28574706
Phosphodiesterase 2A (PDE2A) inhibitors have been reported to demonstrate in vivo activity in preclinical models of cognition. To more fully explore the biology of PDE2A inhibition, we sought to identify...
10.
Hedde J, Hanks A, Schmidt C, Hughes Z
Brain Behav Immun
. 2017 Apr;
64:285-295.
PMID: 28438557
Inhibitors of phosphodiesterase-4 (PDE4) have been approved for the treatment of inflammatory disorders, but are associated with dose-limiting nausea and vomiting. These side effects are hypothesized to be mediated by...